Premature Ejaculation Market - Global Outlook and Forecast 2017-2022

138 pages

54 tables

155 charts

5 region

19 countries

15 company

3 segments

Purchase Options

$3500.00
$4500.00
$5000.00
$1500.00

Have a question?

Please get in touch with our team in case of any queries

+1-312-235-2040

Premature Ejaculation Market - Global Outlook and Forecast 2017-2022

na
Customize this Report

This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize

REPORT ATTRIBUTEDETAILS
Market Size
Market Size
CAGR
Base Year
Historic Year
Forecast Year
Market Segments
Geographic Analysis
Countries Covered
Interested in this Report?

Download a Sample!

The global premature ejaculation market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016−2022. 

Increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management and increasing presence of favorable guidelines, which recommended the use of drugs as first-line therapy for treatment of PE, will augment market prospects during the forecast period. 

A high burden of PE prevalence and associated chronic condition, which can, in turn, poses as a high-risk factor for the occurrence of this disease is the key market driver for the premature ejaculation market in both developing and developed countries. Regionally, the US is the main contributor to the global PE market. Despite the absence of PE drug in the US, the market in North America retains dominant share because of wide accessibility to PE off-labels and OTC drugs. In terms of route of administration, the oral drugs segment contributes a dominant share of nearly three-fourths of the global market.

Premature Ejaculation Market Size in Revenue

The report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and the factors driving its growth. The report also provides information about the latest trends that are likely to become strong market driving forces over the next five years. This report also provides the Porter’s Five Forces analysis along with a description of each force and its impact on the market. Further, the report also provides complete value chain analysis of the global market.

Premature Ejaculation Market: Key Vendor Analysis

The competitive landscape of the premature ejaculation market is concentrated with select players, which occupy a dominant market share. The rest of the market is composed of a plethora of manufacturers offering a generic version of off-label drugs.

  • Innovus Pharma
  • Plethora Solutions
  • Absorption Pharmaceuticals
  • Allergan

Other prominent vendors include Menarini, GlaxoSmithKline, Ixchelsis, Dong-A Pharmaceutical, NeuroHealing Pharmaceuticals.

Premature Ejaculation Market Dynamics

Emphasis on clinical progress of love hormone receptor antagonists to drive the market growth

Increase in prevalence of chronic diseases, low-effectiveness of non-pharmacological treatment, and a wide accessibility to premature ejaculation OTC drugs and generic off-label drugs are the prime factors that are going to escalate the market growth during the forecast period. Furthermore, pharmaceutical advances in PE drug formulation technology, emphasis on clinical progress of love hormone receptor antagonists, and launch of premature ejaculation treatment awareness campaigns are the latest trends that are likely to positively impact the market. The report also provides the key restraints of the market.

Premature Ejaculation MarketSegmental Overview

The amide anesthetics segment is the fast-growing segment in terms of mechanism of action.

The oral drug segment to remain the dominant market in terms of route of administration. The topical PE drugs market is expected to witness growth at a higher pace than the oral drugs market. However, the oral PE drugs market is likely to retain its market share until the end of the forecast period.

In terms of mechanism of action (MOA), the global PE market broad segments include SSRIs, PDE5 inhibitors, and amide anesthetics. In 2016, the SSRIs segment dominated the market. This segment is anticipated to retain its dominance till the end of forecast period. The amide anesthetics segment, which occupied low share in 2016, is anticipated to witness higher growth than the other drug MOAs segment during the period 2016-2022.

Premature Ejaculation MarketGeographical Analysis

North America to remain the largest market followed by Europe

The premature ejaculation market in North America is the largest due to high prevalent PE population. The US occupies approximately 90% of the PE market in North America due to the high population density and comparably higher utilization of off-label and OTC PE products.  Similarly, the UK, Germany, France, Spain, and Italy are the leading markets for PE therapies in the European region. The market in APAC is likely to witness the highest growth rate during the forecast period. A significant increase in PE incidence due to growing burden of chronic conditions, which, in turn, is associated with the high risk of PE occurrence is expected to boost the market growth in this region. The prevalence of PE in the Middle East countries and Latin America is estimated to be lowest than other regions. The market, however, is anticipated to witness a moderate growth rate in these regions.

Frequently Asked Questions

Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan  are the leading companies dominating the premature ejaculation market. The global premature ejaculation (PE) market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016−2022.

Premature ejaculation (PE) is a male sexual dysfunction, which is characterized by the inability to delay ejaculation for more than one minute after penetration or sexual stimulation. The condition is associated with uncontrolled ejaculation either before or shortly after sexual penetration, or with minimal sexual stimulation.

 

Premature Ejaculation Market Segmentation

Report Timeline

  • Base Year:                  2016  
  • Forecast Year:            2017−2022   

Major vendors profiled in the report are as following:

  • Innovus Pharma
  • Plethora Solutions
  • Absorption Pharmaceuticals
  • Allergan

Other prominent vendors include Menarini, GlaxoSmithKline, Ixchelsis, Dong-A Pharmaceutical, NeuroHealing Pharmaceuticals.

Scope of the Report

The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017–2022. It includes a detailed study of growth drivers, trends, and restraints. The report also profiles the leading vendors in the market and other key vendors.

The report provides the analysis of key segments of the market by route administration, mechanism of action, geography, and vendors. It provides a detailed analysis of revenue from various segments:

Route Administration

  • Topical therapies
  • Oral therapy

Mechanism of Action

  • SSRI
  • PDE5 inhibitors
  • Ester/Amide anesthetics

Geography

  • APAC
  • Europe
  • Latin America
  • MEA
  • North America

Major trends, drivers, and restraints for each geography are included in the report.

List Of Exhibits

Exhibit 1         Segmentation of Global PE Market

Exhibit 2         Market Size Calculation Approach 2016

Exhibit 3         Classification of PE

Exhibit 4         Differentiation of Symptoms in PE Sub-types

Exhibit 5         Common Causative Factors for PE

Exhibit 6         PE Prevalence Rate across Various Geographical Regions

Exhibit 7         ISSN Recommended Drug Classes for PE Treatment

Exhibit 8         PE Treatment Algorithm

Exhibit 9         Key Considerations of PE Clinical Trials

Exhibit 10       Key Primary/Secondary Endpoints in PE Clinical Trials

Exhibit 11       Key Hurdles in Research and Innovation of Breakthrough PE Drugs

Exhibit 12       Increase in Global Diabetes Prevalence by Region 2015–2040 (Million)

Exhibit 13       Increase in Global ED Prevalence 1995-2025 (Million)

Exhibit 14       Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)

Exhibit 15       Major Drawbacks of Non-pharmacological PE Treatments

Exhibit 16       PE OTC Drugs Marketing Channels

Exhibit 17       Major Factors Restricting PE Treatment Rate

Exhibit 18       Korean Nation-wide Survey Results 0n Urologists' PE Treatment Rates Per Week (in %) 2012

Exhibit 19       Key Issues Leading to Clinical Trial Terminations/Withdrawal

Exhibit 20       Global PE Market 2016–2022 ($ million)

Exhibit 21       Five Forces Analysis 2016

Exhibit 22       Global PE Market by Route of Administration

Exhibit 23       Percentage Share of Oral and Topical PE Drugs 2016 and 2022

Exhibit 24       Global PE Market by Route of Administration ($ million)

Exhibit 25       Comparison of Growth Rates of Oral and Topical PE Segments

Exhibit 26       Most Common Oral Therapy Drug Types

Exhibit 27       Benefits/Drawbacks Summary of Oral PE Drugs

Exhibit 28       Global PE Oral Therapy Market Size and Forecast ($ million) 2016–2022

Exhibit 29       Available Topical Forms of PE Topical Therapies

Exhibit 30       Benefits/Drawbacks Summary of Topical PE Drugs

Exhibit 31       Global PE Topical Therapy Market Size and Forecast ($ million)

Exhibit 32       Global PE Market by Mechanism of Action

Exhibit 33       Percentage Share of SSRIs, PDE5is, and Amide Anesthetics

Exhibit 34       Global PE Market Lucrativeness by Mechanism of Action

Exhibit 35       Global PE Market by Mechanism of Action ($ million)

Exhibit 36       Comparison of Varying Efficacy of Off-label SSRIs

Exhibit 37       Global SSRI PE Drugs Market Size and Forecast ($ million)

Exhibit 38       Major PDE5i Drug Brands as Off-label PE Medications

Exhibit 39       Global PDE5i PE Therapy Market Size and Forecast ($ million)

Exhibit 40       Common Active Ingredients in Amide Anesthetic PE Formulations

Exhibit 41       Global PDE5i PE Therapy Market Size and Forecast ($ million)

Exhibit 42       Mode of Action of SSRIs

Exhibit 43       Global PE Market by Geography

Exhibit 44       Global PE Market by Geography ($ million)

Exhibit 45       Market Revenue Growth Rates Comparison by Geography

Exhibit 46       Global PE Market Lucrativeness by Geography 2022

Exhibit 47       PE Market in North America by Country 2016

Exhibit 48       Prevalence of PE in North America

Exhibit 49       PE Market in North America 2016–2022 ($ million)

Exhibit 50       PE Market in US 2016–2022 ($ million)

Exhibit 51       PE Market in Canada 2016–2022 ($ million)

Exhibit 52       Key PE Market Dynamics in North America

Exhibit 53       PE Market in Europe by Country 2016

Exhibit 54       Prevalence Trend of Prostate Cancer Holding High Associated Risk for PE Incidence in Europe 2012–2020 (thousand)

Exhibit 55       PE Market in Europe ($ million)

Exhibit 56       PE Market in Germany 2016–2022 ($ million)

Exhibit 57       PE Market in UK ($ million)

Exhibit 58       PE Market in France ($ million)

Exhibit 59       PE Market in Italy ($ million)

Exhibit 60       PE Market in Spain ($ million)

Exhibit 61       Key PE Market Dynamics in Europe

Exhibit 62       PE Market in APAC ($ million)

Exhibit 63       PE Market in Japan 2016–2022 ($ million)

Exhibit 64       PE Market in Australia ($ million)

Exhibit 65       PE Market in China ($ million)

Exhibit 66       PE Market in India ($ million)

Exhibit 67       Key PE Market Dynamics in APAC

Exhibit 68       PE Market in Latin America ($ million)

Exhibit 69       Key PE Market Dynamics in Latin America

Exhibit 70       PE Market in MEA 2016–2022 ($ million)

Exhibit 71       Key PE Market Dynamics in Latin America

Exhibit 72       Strategic Recommendation for Market Participants

           

           

TABLES          

Table 1            Key Geographies Definition

Table 2            Key Caveats

Table 3            Currency Conversion 2013−2016

Table 4            Early Definitions of Premature Ejaculation

Table 5            Summary of PE Epidemiology Studies

Table 6            Recommended/Optional Questions to Establish Diagnosis and Treatment of PE

Table 7            Summary of PE Validated Questionnaires

Table 8            Summary of Commonly Recommended PE Drugs

Table 9            Key Pipeline PE Drug Molecules

Table 10         Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules

Table 11         Epelsiban Product Profile

Table 12         IX-01 Product Profile

Table 13         DA-8031 Product Profile

Table 14         Recommended Drugs for PE Treatment

Table 15         Major Unmet Need in PE Market

Table 16         YOY Impact of Market Enablers 2016–2022

Table 17         Key Terminated/Withdrawn Investigational PE Drugs

Table 18         YOY Impact of Market Restraints 2016–2022

Table 19         Marketed PE Drugs with Meter-Dose Delivery Systems

Table 20         Pipeline Oxytocin Receptor Antagonists

Table 21         YOY Impact of Trends and Opportunities 2016–2022

Table 22         Global PE Market by Route of Administration 2016–2022 ($ million)

Table 23         Key Topical Therapy PE Drugs by Type of Formulation

Table 24         Global PE Market by Mechanism of Action 2016–2022 ($ million)

Table 25         Commonly Used Topical PE OTC Ester/Amide Anesthetic

Table 26         Global PE Market by Geography 2016–2022 ($ million)

Table 27         Key PE Campaigns Launched in Europe

Table 28         Competitive Structure Analysis of Global PE Market 2016

Table 29         Therapeutic Area and Products of Innovus

Table 30         Qualitative Summary of Global PE Market

Table 31         Quantitative Summary of Global PE Market by Geography ($ million)

Table 32         Quantitative Summary of Global PE Market by Geography (Revenue %)

Table 33         Quantitative Summary of Global PE Market by Route of Administration ($ million)

Table 34         Quantitative Summary of Global PE Market by Mechanism of Action ($ million)

 

1          Research Methodology

2          Research objectives

3          Research process

4          Report Coverage

4.1       Market Definition

4.2       Base Year

4.3       Scope of Study

4.3.1   Market Segmentation by Route of Administration

4.3.2   Market Segmentation by Mechanism of Action

4.3.3   Market Segmentation by Geography

 

5          Report Assumptions & Caveats

5.1       Currency Conversion rate

5.2       Market Derivation

 

6          Market at a Glance

7          Introduction

7.1       Definition Of Premature Ejaculation

7.2       Disease Overview

7.3       CLASSIFICATION OF Premature Ejaculation

7.3.1   Lifelong PE

7.3.2   Acquired PE

7.3.3   Variable PE

7.3.4   Subjective EjD

7.4       Symptoms Of Premature Ejaculation (Pe)

7.5       Aetiology OF Premature Ejaculation

7.5.1   Physiological Factors

7.5.2   Biological Factors

7.5.3   Genetic Factors

7.5.4   Co-morbidity

7.6       Epidemiology

8          ISSN Guidelines ON PE

8.1       Disease Assessment

8.1.1   Patient History

8.1.2   Physical Examination

8.1.3   Assessment Instruments

8.2       Treatment

8.2.1   Physiological Therapy

8.2.2   Behavioral Techniques

8.2.3   Pharmacological Treatment

 

9          Clinical Trial Landscape

9.1       Overview

9.1.1   Trial Subjects Selection Criteria

9.1.2   Trial Design Considerations

9.1.3   Trial Data Evaluation Considerations

9.2       Clinical Trial EndPoints

 

10        Pipeline Landscape

10.1    Overview

10.2    Key Pipeline Drug Candidates

10.3    Dormant/Terminated/Withdrawn Drug Candidates

10.4    Key Product Profiles

10.5    Epelsiban

10.5.1 Overview

10.5.2 Product Profile

10.5.3 Future Outlook

10.6    IX-01

10.6.1 Overview

10.6.2 Product Profile

10.6.3 Future Outlook

10.7    DA-8031

10.7.1 Overview

10.7.2 Product Profile

10.7.3 Future Outlook

 

11        Marketed Products Landscape

11.1    overview

11.2    Recommended Marketed Drugs

 

12        Market Dynamics

12.1    Market Growth Enablers

12.1.1 Increase in Prevalence of Chronic Diseases

12.1.2 Low-effectiveness of Non-pharmacological PE Treatment

12.1.3 High Unmet Need

12.1.4 Wide Accessibility to PE OTC Drugs and Generic Off-label Drugs

12.1.5 YOY Impact of Market Enablers

12.2    Market Growth Restraints

12.2.1 Low Treatment Seeking Patient Pool

12.2.2 Associated Adverse Effects of PE Drugs

12.2.3 Clinical Trial Withdrawals/Terminations

12.2.4 YOY Impact of Market Restraints

12.3    Market Opportunities & Trends

12.3.1 Advances in PE Drug Formulation Technologies

12.3.2 Emphasis on Clinical Progress of Love Hormone Receptor Antagonists

12.3.3 Launch of PE Awareness Campaigns

12.3.4 YOY Impact of Trends and Opportunities

 

13        Global Premature Ejaculation Market

13.1    market Overview

13.2    Market Size & Forecast

13.3    Porter’s Five Forces Analysis

13.3.1 Threat of New Entrants

13.3.2 Bargaining Power of Suppliers

13.3.3 Bargaining Power of Buyers

13.3.4 Threat of Substitutes

13.3.5 Competitive Rivalry

14        PreMature Ejaculation Market- By Route Of Administration

14.1    Segment Overview

14.2    PE ORAL THERAPY Market

14.3    PE TOPICAL THERAPY MARKET

 

15        PreMature Ejaculation Market - By Mechanism Of Action

15.1    Segment Overview

15.2    SSRI PE Therapy Market

15.2.1 Market Size & Forecast

15.3    PDE5i PE Therapy Market

15.3.1 Market Size & Forecast

15.4    AMIDE/ESTER ANESTHETIC PE Therapy Market

15.4.1 Market Size & Forecast

 

16        Premature Ejaculation Market By Geography

16.1    Market Overview

 

17        North America: Premature Ejaculation Market

17.1    Market Overview

17.2    Market Size & Forecast

17.3    Key Countries

17.3.1 US: Market Size & Forecast

17.3.2 Canada: Market Size & Forecast

17.4    Leading Trends, Enablers, and Restraints

 

18        Europe: Premature Ejaculation Market

18.1    Market Overview

18.2    Market Size & Forecast

18.3    Key Countries

18.3.1 Germany: Market Size & Forecast

18.3.2 UK: Market Size & Forecast

18.3.3 France: Market Size & Forecast

18.3.4 Spain and Italy: Market Size & Forecast

18.4    Leading Trends, Enablers, and Restraints

 

19        APAC: Premature Ejaculation MARKET

19.1    Market Overview

19.2    Market Size & Forecast

19.3    Key Countries

19.3.1 Japan: Market Size & Forecast

19.3.2 Australia: Market Size & Forecast

19.3.3 China and India: Market Size & Forecast

19.4    Leading Trends, Enablers, and Restraints

 

20        Latin America: Premature Ejaculation Market

20.1    Market Overview

20.2    Market Size & Forecast

20.3    Major Trends, Enablers, and Restraints

 

21        MEA: Premature Ejaculation Market

21.1    Market Overview

21.2    Market Size & Forecast

21.3    Major Trends, Enablers, and Restraints

 

22        Competitive Landscape

22.1    Strategic Recommendation for Market Participants

 

23        Key Company Profiles

23.1    Innovus Pharmaceuticals INC.

23.1.1 Strength Assessment

23.1.2 Strategy Assessment

23.1.3 Opportunity Assessment

23.2    Plethora Solutions Holdings PLC

23.2.1 Strength Assessment

23.2.2 Strategy Assessment

23.2.3 Opportunity Assessment

23.3    Absorption Pharmaceuticals LLC

23.3.1 Strength Assessment

23.3.2 Strategy Assessment

23.3.3 Opportunity Assessment

23.4    Allergen PLC

23.4.1 Strength Assessment

23.4.2 Strategy Assessment

23.4.3 Opportunity Assessment

 

24        Other Prominent Companies

24.1    Menrnani

24.1.1 Strength Assessment

24.1.2 Strategy Assessment

24.1.3 Opportunity Assessment

24.2    GlaxoSmithKline plc

24.2.1 Strength Assessment

24.2.2 Strategy Assessment

24.2.3 Opportunity Assessment

24.3    Ixchelsis Ltd

24.3.1 Strength Assessment

24.3.2 Strategy Assessment

24.3.3 Opportunity Assessment

24.4    DONG-A- Pharmaceuticals Co. Ltd.

24.4.1 Strength Assessment

24.4.2 Strategy Assessment

24.4.3 Opportunity Assessment

24.5    NeuroHealing Pharmaceuticals Inc.

24.5.1 Strength Assessment

24.5.2 Strategy Assessment

24.5.3 Opportunity Assessment

 

25        Report Summary

25.1    Key Takeaways

25.2    Qualitative Summary of Global PRE-Mature Ejaculation Market

25.3    Quantitative Summary of Global PRe-Mature Ejaculation Market

 

26        Appendix

26.1    List of Abbreviations

           

           

           

 

           

 

 

Select a license type that suits your business needs

Single User Licence

$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email

5 User Licence

$4500.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Corporate Licence

$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Datasheet Licence

$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Frequently Asked Questions